Everest Medicines Limited (FRA:6HN)

Market Cap	1.08B -52.2%
Revenue (ttm)	310.34M +182.9%
Net Income	-6.95M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	29.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.900
Previous Close	2.800
Day's Range	2.900 - 2.900
52-Week Range	2.480 - 6.300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 20, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 812
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6HN

Financial Performance

In 2025, Everest Medicines's revenue was 1.71 billion, an increase of 141.51% compared to the previous year's 706.68 million. Losses were -297.77 million, -71.41% less than in 2024.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error